Deirdre Dunne
@dunnedeirdre.bsky.social
Executive Publisher @ Elsevier
Working together with the European Society for Medical Oncology (ESMO)
Working together with the European Society for Medical Oncology (ESMO)
Today’s Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
October 19, 2025 at 11:26 AM
Today’s Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
The First Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
October 18, 2025 at 8:02 AM
The First Annals of Oncology and ESMO Open Concomitant publications are available online:
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
www.annalsofoncology.org/concomitant
@myesmo.bsky.social #ESMO25
An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers!
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
March 20, 2025 at 8:07 PM
An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers!
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
Congratulations to the Editorial team on reaching this important milestone.
The inaugural issue is online:
www.esmorarecancers.org/current
New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial
www.sciencedirect.com/science/arti... #ESMO
www.sciencedirect.com/science/arti... #ESMO
December 4, 2024 at 5:52 AM
New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial
www.sciencedirect.com/science/arti... #ESMO
www.sciencedirect.com/science/arti... #ESMO
📖 #AnnalsOfOncology #DYK
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
December 4, 2024 at 5:48 AM
📖 #AnnalsOfOncology #DYK
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology
🔗 ow.ly/exiT50UgvZl
I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology
www.esmorarecancers.org/article/S305...
www.esmorarecancers.org/article/S305...
November 26, 2024 at 12:24 PM
I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology
www.esmorarecancers.org/article/S305...
www.esmorarecancers.org/article/S305...
📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO
🔗 ow.ly/9LCT50U8U9f
🔗 ow.ly/9LCT50U8U9f
November 25, 2024 at 9:09 AM
📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO
🔗 ow.ly/9LCT50U8U9f
🔗 ow.ly/9LCT50U8U9f
👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25
🔗 ow.ly/bxph50Ua6zJ
🔗 ow.ly/bxph50Ua6zJ
November 22, 2024 at 11:59 AM
👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25
🔗 ow.ly/bxph50Ua6zJ
🔗 ow.ly/bxph50Ua6zJ
📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO
🔗 ow.ly/uC6R50UbLJE
🔗 ow.ly/uC6R50UbLJE
November 22, 2024 at 11:52 AM
📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO
🔗 ow.ly/uC6R50UbLJE
🔗 ow.ly/uC6R50UbLJE
📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023?
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
November 21, 2024 at 10:27 AM
📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023?
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
#CancerResearch #AnnalsOfOncology
🔗 ow.ly/9AYe50U7MNP
📖 To mark 35 years of Annals of Oncology, putting a 2023 top-cited paper in the spotlight: "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types."
#AnnalsOfOncology
🔗 ow.ly/pbE650U7MPt
#AnnalsOfOncology
🔗 ow.ly/pbE650U7MPt
November 21, 2024 at 10:26 AM
📖 To mark 35 years of Annals of Oncology, putting a 2023 top-cited paper in the spotlight: "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types."
#AnnalsOfOncology
🔗 ow.ly/pbE650U7MPt
#AnnalsOfOncology
🔗 ow.ly/pbE650U7MPt
#ESMOImmuno24: 🚨 Last Chance to Save on Registration 🚨
Exciting times ahead! Late-breaking abstract authors-titles are now online!
👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there!
🔗https://ow.ly/QvNu50U483r
Exciting times ahead! Late-breaking abstract authors-titles are now online!
👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there!
🔗https://ow.ly/QvNu50U483r
November 19, 2024 at 8:43 AM
#ESMOImmuno24: 🚨 Last Chance to Save on Registration 🚨
Exciting times ahead! Late-breaking abstract authors-titles are now online!
👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there!
🔗https://ow.ly/QvNu50U483r
Exciting times ahead! Late-breaking abstract authors-titles are now online!
👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there!
🔗https://ow.ly/QvNu50U483r
👉 Discover how to implement the ESMO Guidelines in real-world clinical scenarios and contribute to a richer learning experience by submitting your questions to the experts.
🔗 ow.ly/3v8h50U67lG
🔗 ow.ly/3v8h50U67lG
November 19, 2024 at 8:11 AM
👉 Discover how to implement the ESMO Guidelines in real-world clinical scenarios and contribute to a richer learning experience by submitting your questions to the experts.
🔗 ow.ly/3v8h50U67lG
🔗 ow.ly/3v8h50U67lG
Annals of Oncology received its first impact factor in 1994, a key achievement in #oncology publishing. 3 decades later the IF stands at 56.7, ranking 4th in oncology
www.sciencedirect.com/journal/anna...
www.sciencedirect.com/journal/anna...
November 19, 2024 at 8:09 AM
Annals of Oncology received its first impact factor in 1994, a key achievement in #oncology publishing. 3 decades later the IF stands at 56.7, ranking 4th in oncology
www.sciencedirect.com/journal/anna...
www.sciencedirect.com/journal/anna...
📖 #AnnalsOfOncology #DYK In December 1990 Annals of Oncology published its first ESMO Congress abstract book, featuring 481 abstracts from 25 countries.
🔗 ow.ly/EZc450U6NfO
🔗 ow.ly/EZc450U6NfO
November 19, 2024 at 8:04 AM
📖 #AnnalsOfOncology #DYK In December 1990 Annals of Oncology published its first ESMO Congress abstract book, featuring 481 abstracts from 25 countries.
🔗 ow.ly/EZc450U6NfO
🔗 ow.ly/EZc450U6NfO
📖 #AnnalsOfOncology #MilestonesMonday: In 2000, David Kerr succeeded Franco Cavalli to become the second Editor-in-Chief of Annals of Oncology shaping its next decade of impactful publications.
ow.ly/NiT850U6N8i
ow.ly/NiT850U6N8i
November 19, 2024 at 8:03 AM
📖 #AnnalsOfOncology #MilestonesMonday: In 2000, David Kerr succeeded Franco Cavalli to become the second Editor-in-Chief of Annals of Oncology shaping its next decade of impactful publications.
ow.ly/NiT850U6N8i
ow.ly/NiT850U6N8i
Check out this new study published in ESMO Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆
www.sciencedirect.com/science/arti...
@ptarantinomd.bsky.social
www.sciencedirect.com/science/arti...
@ptarantinomd.bsky.social
November 18, 2024 at 9:33 PM
Check out this new study published in ESMO Open looking at clinical outcomes of early stage #TripleNegativeBreastCancer after neoadjuvant chemotherapy according to #HER2low status☆
www.sciencedirect.com/science/arti...
@ptarantinomd.bsky.social
www.sciencedirect.com/science/arti...
@ptarantinomd.bsky.social
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy - published in ESMO Open #precisionmedicine
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
November 18, 2024 at 9:09 PM
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy - published in ESMO Open #precisionmedicine
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
🎧Article of the month: listen to the new podcast in which Annals of Oncology Editor-in-Chief Tom Powles discusses the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial with Dr Toon Van Gorp of the Leuven Cancer Institute, Belgium.
soundcloud.com/esmo-podcast...
soundcloud.com/esmo-podcast...
November 18, 2024 at 8:57 PM
🎧Article of the month: listen to the new podcast in which Annals of Oncology Editor-in-Chief Tom Powles discusses the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial with Dr Toon Van Gorp of the Leuven Cancer Institute, Belgium.
soundcloud.com/esmo-podcast...
soundcloud.com/esmo-podcast...
New Annals of Oncology article in press: A phase III randomized trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
annalsofoncology.org/retrieve/pii...
annalsofoncology.org/retrieve/pii...
November 18, 2024 at 8:55 PM
New Annals of Oncology article in press: A phase III randomized trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
annalsofoncology.org/retrieve/pii...
annalsofoncology.org/retrieve/pii...
📖 #AnnalsOfOncology #MilestonesMonday: The very first issue of Annals of Oncology was published in January 1990 with Franco Cavalli as founding Editor-in-Chief. Since then, it’s been a key resource for Oncology Research and practice worldwide.
🔗 ow.ly/wHRu50U6MWV
🔗 ow.ly/wHRu50U6MWV
November 18, 2024 at 8:52 PM
📖 #AnnalsOfOncology #MilestonesMonday: The very first issue of Annals of Oncology was published in January 1990 with Franco Cavalli as founding Editor-in-Chief. Since then, it’s been a key resource for Oncology Research and practice worldwide.
🔗 ow.ly/wHRu50U6MWV
🔗 ow.ly/wHRu50U6MWV
📖 ESMO invites you to mark Annals of Oncology’s 35th Anniversary by exploring significant milestones with the Milestones Monday series, the #DYK post series, exclusive interviews with Editors-in-Chief, and the 2023 most-cited papers
🔗 ow.ly/8rwR50U6a4t
🔗 ow.ly/8rwR50U6a4t
November 18, 2024 at 8:51 PM
📖 ESMO invites you to mark Annals of Oncology’s 35th Anniversary by exploring significant milestones with the Milestones Monday series, the #DYK post series, exclusive interviews with Editors-in-Chief, and the 2023 most-cited papers
🔗 ow.ly/8rwR50U6a4t
🔗 ow.ly/8rwR50U6a4t
📢New guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
linkinghub.elsevier.com/retrieve/pii...
linkinghub.elsevier.com/retrieve/pii...
November 18, 2024 at 8:48 PM
📢New guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
linkinghub.elsevier.com/retrieve/pii...
linkinghub.elsevier.com/retrieve/pii...
Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail bit.ly/2WfW9Cb or subscribe to our RSS bit.ly/2yRH9Cp
November 18, 2024 at 8:46 PM
Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail bit.ly/2WfW9Cb or subscribe to our RSS bit.ly/2yRH9Cp
I’m thrilled to announce the launch of ESMO Rare Cancers! This new journal aims to enhance the understanding and management of rare malignancies. Join us in sharing impactful research and improving patient outcomes. Learn more: spkl.io/8283
November 18, 2024 at 8:42 PM
I’m thrilled to announce the launch of ESMO Rare Cancers! This new journal aims to enhance the understanding and management of rare malignancies. Join us in sharing impactful research and improving patient outcomes. Learn more: spkl.io/8283